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general practice. The mortality rate ratio was calculated and prevalence of depres-
sion compared. Additionally descriptive, non-comparative analysis of key clinical 
manifestations was presented. Results: We identified 605 subjects with CAH (41% 
male). Mean age at presentation was 11.0 (sd 19.9) years for males, 13.6 (sd 17.4) for 
females. 58% of subjects were diagnosed ≤ 6 years old. 562 patients with CAH (93%) 
could each be matched with 10 controls. The crude rate ratio for all-cause mortality 
in CAH vs. controls was 2.6 (95%CI 1.7–3.9). Lifetime prevalence of depression in CAH 
was 33% vs. 26% in controls (p< 0.001). In females the following morbidities were 
reported: adrenal crisis, hyponatraemia, 39 (11%); genital anomalies/surgery, 129 
(36%); precocious puberty, 34 (10%); hirsutism, virilism, 65 (18%); polycystic ovarian 
syndrome, 36 (10%); oligo/amenorrhoea, 42 (12%); infertility, 37 (10%). In males the 
following were reported: adrenal crisis, hyponatraemia, 30 (12%); precocious puberty, 
20 (8%); infertility, 12 (5%). ConClusions: Patients with CAH had significantly 
reduced survival and increased prevalence of depression compared with matched 
controls. Novel approaches to treating CAH that can alleviate the impact of this 
condition are required urgently.
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objeCtives: Autism, a heterogeneous disease, is described as a genetic psychiatry 
disorder. Multiple lines of evidence support the notion that most cases of autism 
likely have an underlying genetic cause or predisposition. Since folate and methyla-
tion (single carbon metabolism) are vital in neurological development, we routinely 
screened children for the common mutations of the methylenetetrahydrofolate 
reductase gene (MTHFR), which regulates this pathway. Common polymorphisms 
in the MTHFR gene have been associated with reduced enzyme activity. The study 
aims to analyze the chromosome alterations and rare mutations in MTHFR and its 
association in Autism patients. Methods: In the present study, in order to inves-
tigate the possible cytogenetic damage using peripheral blood lymphocyte culture 
(PBLC), and rare mutations of MTHFRthat have been reported to be associated with 
autism patients using PCR – SSCP method, and was carried out in the 25 autistic 
patient samples, based on the detailed DSM - IV questionnaire, and equal number 
of controls were selected. Results: In our study chromosomal alterations were 
frequently observed in chromosomes 2, 3, 7, 22 and X (2q32, 3q25-q27). In the present 
study, chromosomal aberrations showed higher degree in experimentals compared 
to controls (P< 0.001). We analysed the association between three single nucleotide 
polymorphisms (SNPs) of the MTHFR gene. No significant evidence between any 
SNPs of MTHFRgene in autism was observed. ConClusions: In conclusion, in 
this pilot study, we observed that the identification of cytogenetic abnormalities is 
not only important for providing a cause for the autism in a single individual but 
is also critical for accurate counselling regarding recurrence risks to parents and 
family members. We suggest that MTHFRmight represent a major susceptibility 
gene for autism.
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objeCtives: Rett syndrome (RTT) is a neurodevelopmental disorder that affects 
girls almost exclusively. This study aims to identify the genetic alterations of RTT 
by using the conventional cytogenetic techniques Trypsin G- banding with Mecp2 
genotype, and to estimate the role of association in Dopamine and serotonin lev-
els as a consequence of neurotransmitters. Methods: A total of 13 RTT patients 
were evaluated based on the Diagnostic and statistical manual of the American 
psychiatric association (DSM-IV). Human Peripheral blood Leukocyte culture for 
chromosomal analysis was screened, the genotypic polymorphism was analysed 
using the PCR-RFLP methods and Plasma GABA analysis and serotonin levels were 
also measured. Results: Abnormal karyotypes were found in the chromosomes 
17, 21, 22 and X. C to T transition in exon 2 of Mecp2 resulting in R106W amino 
acid substitution. 316 C to T transition nucleotide changes and R106W amino acid 
changes were observed in 7 subjects, 824delcins11 were seen in 4 subjects, 916 C 
to T nucleotide and R294W amino acid change in 2 patient each. Higher frequency 
of XCI was observed in subjects with severe RTT (Max. 95.5%). Among the neuro-
transmitter levels, elevated level of Dopamine and serotonin levels (p> -001) was 
measured. ConClusions: In conclusion, in this pilot study, we observed that the 
identification of cytogenetic abnormalities is not only important for providing a 
cause for the RTT in a single individual of twins and is also critical for accurate 
counseling regarding recurrence risks to parents and family members. Although 
these findings should interpret with caution, and larger, more standardized stud-
ies are warranted.Key Words: Rett syndrome, MECP2 mutation, neurotransmitters, 
chromosomal analysis
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objeCtives: To assess the effectiveness of CBL gene Mutation, which is a test per-
formed to check for mutations in the CBL (Casitas B-lineage Lymphoma) gene by 
sequencing in order to diagnose juvenile myelomonocytic leukemia (JMML) and 
determine the treatment strategy. Methods: We searched the 8 Korean databases 
within the Onabotulinum arm, and pain, constipation, dizzliness, and skin rush 
for triptans. ConClusions: Overall, Onabotulinum Toxin, a novel intravenous 
agent for the phrophylaxis treatment of Chronic Migraine, is well tolerated, and 
offer better tolerance and adherence in comparison with Oral Triptans.
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objeCtives: Once daily oral fingolimod (FTY720; Gilenya®, Novartis Pharma AG), 
is approved for the treatment of relapsing remitting multiple sclerosis(RRMS) in 
over 80 countries. As of February 2015, it is estimated that Gilenya® has been used 
to treat approximately 119,000 patients. The total patient exposure is approxi-
mately 218,500 patient years. PANGAEA (Post-Authorization Non-interventional 
German sAfety study of GilEnyA in RRMS patients) is a non-interventional study, 
conducted in Germany, to investigate long-term safety, tolerability and effective-
ness of fingolimod in daily clinical practice. Here we present data of the 36 months 
interim-analysis. Methods: Recruitment into PANGAEA finished in December 
2013. 4229 patients were enrolled. In this interim-analysis we present data from 
patients that are treated with fingolimod for up to 36 months. Results: The 
proportion of female patients was 71.6% and the mean age was 39.4 ±10.0 years. 
The annualized relapse rate of all PANGAEA patients improved from 1.5 (baseline) 
to 0.43 (month 12), 0.41 (month 24) and 0.37 (month 36). Of all enrolled PANGAEA 
patients 67.9% in the first, 68.3% in the second and 70.1% in the third year were 
relapse free. The mean EDSS of all PANGAEA patients was stable over 36 months 
at 3.0. In year 3 of PANGAEA 70.5% of the patients had no clinical disease activity 
measured by relapses and sustained EDSS progression. 10.8% of the patients dis-
continued the Fingolimod therapy in the first year (9.1% second year), 4,3% (2.3% 
second year) because of adverse events. 45.4% of the patients experienced no 
adverse events. Patients treatment satisfaction measured by the TSQM (Treatment 
Satisfaction Questionnaire for Medication)-9 Score, improved by 3 points over 
24 months. ConClusions: The results of the 36 months interim analysis of 
PANGAEA support the positive safety and effectiveness profile demonstrated in 
phase the III clinical trials. PANGAEA is a valuable source data for patients treated 
with fingolimod in daily clinical routine.
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objeCtives: Over the past 20 years, there have been research efforts, global ini-
tiatives, and new therapies aimed at awareness, diagnosis, and care of individuals 
with Alzheimer’s disease (AD). The OptumLabsTM Data Warehouse (OLDW), a large 
database including administrative claims data on privately insured and Medicare 
Advantage enrollees, was used to investigate 20-year trends in AD diagnoses and 
AD-specific drug prescribing. Methods: Demographics and prevalence of AD, as 
well as prescription counts for the treatment of AD were evaluated among individu-
als enrolled each year from 1996 to 2014. Prescription counts for the treatment of 
AD were identified as the number of individuals with at least one 30-day fill for 
a medication used to treat AD per year during the study period. New cases of AD 
were identified if they received a second AD diagnosis and/or were prescribed an 
AD-specific medication within six months of initial diagnosis. Additionally, individu-
als with major psychoses prior to AD diagnosis were excluded. Time trends were 
examined. Results: Prevalence of AD grew from 4 per 10,000 to 70 per 10,000 lives 
over time with the largest increase between 2005 and 2010. The majority of AD cases 
were female, Caucasian, and over 65 years of age at diagnosis. On average, 3,522 
new cases of AD were diagnosed annually. Donezipil has been the most commonly 
prescribed treatment for AD since its approval in 1997 followed by namenda, which 
was approved in 2003. In 2014, 51% and 30% of individuals with AD had at least 
one 30-day prescription for donezipil and namenda, respectively. ConClusions: 
Increased awareness, improved guidelines for diagnosis and more treatment options 
have contributed to a 23 fold-increase in AD diagnoses and subsequent increase in 
treatment over the last two decades.
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objeCtives: Congenital adrenal hyperplasia (CAH) comprises a group of disorders 
in which cortisol synthesis is disrupted. It may result in life-threatening adrenal 
crises and in symptoms such as genital ambiguity and hirsutism in females, preco-
cious puberty, and infertility, with associated effects on well-being. The purpose of 
this study was to evaluate all-cause mortality and depression and to characterise 
clinical manifestations of CAH in a UK primary-care population. Methods: Data 
were from the UK Clinical Practice Research Datalink (CPRD). Patients with a diag-
nosis of CAH and at least one prescription for a corticosteroid were selected, and 
matched 1:10 to a randomly drawn control group without CAH on gender, age and 
